European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (Nasdaq: EBAC) is a blank-check company formed to identify and complete a merger or acquisition within the European biotechnology and life sciences sector. The SPAC completed its initial public offering in 2021 and remained in its search phase at the time of its quarterly report filed on August 15, 2022, recorded under SEC accession number 0001193125-22-221316. Targeting the European biotech landscape, EBAC sought to capitalize on a deep regional pipeline of clinical-stage and commercial-stage biopharmaceutical innovators. To access full sponsor details, deal timeline, filing history, and comparable SPAC analytics for EBAC, sign up for a SpacDesk account at spacdesk.com.